GPCR Inhibition in Treating Lymphoma.

ACS Med Chem Lett

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

Published: March 2022

G protein-coupled receptors (GPCRs) are important classes of cell surface receptors involved in multiple physiological functions. Aberrant expression, upregulation, and mutation of GPCR signaling pathways are frequent in many types of cancers, promoting hyperproliferation, angiogenesis, and metastasis. Recent studies showed that alterations of GPCRs are involved in different lymphoma types. Herein, we review the synthetic strategies to obtain GPCR inhibitors, focusing on CXCR4 inhibitors which represent most of the GPCR inhibitors available in the market or under preclinical investigations for these diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10796172PMC
http://dx.doi.org/10.1021/acsmedchemlett.1c00600DOI Listing

Publication Analysis

Top Keywords

gpcr inhibitors
8
gpcr
4
gpcr inhibition
4
inhibition treating
4
treating lymphoma
4
lymphoma protein-coupled
4
protein-coupled receptors
4
receptors gpcrs
4
gpcrs classes
4
classes cell
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!